Identification of a New Region of SARS-CoV S Protein Critical for Viral Entry

Journal of Molecular Biology

Volumn 394, Issue 4, 2009, Pages 600-605

  Guo, Ying ^a   Tisoncik, Jennifer ^a   McReynolds, Susanna ^a   Farzan, Michael ^b   Prabhakar, Bellur S ^a   Gallagher, Thomas ^c   Rong, Lijun ^a   Caffrey, Michael ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

^b Partners AIDS Research Center   (United States)

^c LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

envelope; mutagenesis; SARS CoV; spike; viral entry

Indexed keywords

ALANINE; ANGIOTENSIN CONVERTING ENZYME 2; VIRUS SPIKE PROTEIN;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; CELL STRAIN HEK293; CONTROLLED STUDY; EMBRYO; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; MOLECULAR LIBRARY; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PSEUDOTYPING; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; VIRION; VIRUS ENTRY; VIRUS INHIBITION;

HUMAN IMMUNODEFICIENCY VIRUS; SARS CORONAVIRUS;

EID: 70449525126     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2009.10.032     Document Type: Article

References (29)

1. Ksiazek T.G., Erdman D., Goldsmith C.S., Zaki S.R., Peret T., Emery S., et al. A novel coronavirus associated with severe acute respiratory syndrome. N. Engl. J. Med. 348 (2003) 1953-1966
2. Drosten C., Günther S., Preiser W., van der Werf S., Brodt H.R., Becker S., et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N. Engl. J. Med. 348 (2003) 1967-1976
3. Marra M.A., Jones S.J., Astell C.R., Holt R.A., Brooks-Wilson A., and Butterfield Y.S. The Genome sequence of the SARS-associated coronavirus. Science 300 (2003) 1399-1404
4. Rota P.A., Oberste M.S., Monroe S.S., Nix W.A., Campagnoli R., Icenogle J.P., et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 300 (2003) 1394-1399
5. Simmons G., Reeves J.D., Rennekamp A.J., Amberg S.M., Piefer A.J., and Bates P. Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry. Proc. Natl Acad. Sci. USA 101 (2004) 4240-4245
6. Tripet B., Howard M.W., Jobling M., Holmes R.K., Holmes K.V., and Hodges R.S. Structural characterization of the SARS-coronavirus spike S fusion protein core. J. Biol. Chem. 279 (2004) 20836-20849
7. Hakansson-McReynolds S., Jiang S., Rong L., and Caffrey M. The solution structure of the severe acute respiratory syndrome-coronavirus heptad repeat 2 in the prefusion state. J. Biol. Chem. 281 (2006) 11965-11971
8. McReynolds S., Jiang S., Ying G., Celigoy J., Schar C., Rong L., and Caffrey M. Characterization of the prefusion and transition states of severe acute respiratory syndrome coronavirus S2-HR2. Biochemistry 47 (2008) 6802-6808
9. Gallagher T.M., and Buchmeier M.J. Coronavirus spike proteins in viral entry and pathogenesis. Virology 279 (2001) 371-374
10. Navas-Martin S., and Weiss S.R. SARS: lessons learned from other coronaviruses. Viral Immunol. 16 (2003) 461-474
11. Simmons G., Reeves J., Rennekamp A., Amberg S., Piefer A., and Bates P. Characterization of severe acute respiratory syndrome-associated coronavirus (SARS CoV) spike glycoprotein-mediated viral entry. Proc. Natl Acad. Sci. USA 101 (2004) 4240-4245
12. Huang I., Bosch B., Li F., Li W., Lee K., Ghiran S., et al. SARS coronavirus, but not human coronavirus NL63, utilizes cathepsin L to infect ACE2-expressing cells. J. Biol. Chem. 281 (2005) 3198-3203
13. Belouzard S., Chu V.C., and Whittaker G.R. Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites. Proc. Natl Acad. Sci. USA 106 (2009) 5871-5876
14. Li W., Moore M.J., Vasilieva N., Sui J., Wong S.K., Berne M.A., et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426 (2003) 450-454
15. Jeffers S.A., Tusell S.M., Gillim-Ross L., Hemmila E.M., Achenbach J.E., Babcock G.J., et al. CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus. Proc. Natl Acad. Sci. USA 101 (2004) 15748-15753
16. Babcock G.J., Esshaki D.J., Thomas W.D., and Ambrosino D.M. Amino acids 270 to 510 of the severe acute respiratory syndrome coronavirus spike protein are required for interaction with receptor. J. Virol. 78 (2004) 4552-4560
17. Wong S.K., Li W., Moore M.J., Choe H., and Farzan M.A. A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2. J. Biol. Chem. 279 (2004) 3197-3201
18. Xiao X., Chakraborti S., Dimitrov A.S., Gramatikoff K., and Dimitrov D.S. The SARS-CoV S glycoprotein: expression and functional characterization. Biochem. Biophys. Res. Commun. 312 (2003) 1159-1164
19. Liu S., Xiao G., Chen Y., He Y., Niu J., Escalante C.R., et al. Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors. Lancet 363 (2004) 938-947
20. Bosch B.J., Martina B.E., Van Der Zee R., Lepault J., Haijema B.J., Versluis C., et al. Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides. Proc. Natl Acad. Sci. USA 101 (2004) 8455-8460
21. Guillén J., Pérez-Berná A.J., Moreno M.R., and Villalaín J. Identification of the membrane-active regions of the severe acute respiratory syndrome coronavirus spike membrane glycoprotein using a 16/18-mer peptide scan: implications for the viral fusion mechanism. J. Virol. 79 (2005) 1743-1752
22. Sui J., Li W., Roberts A., Matthews L.J., Murakami A., Vogel L., et al. Evaluation of human monoclonal antibody 80R for immunoprophylaxis of severe acute respiratory syndrome by an animal study, epitope mapping, and analysis of spike variants. J. Virol. 79 (2005) 5900-5906
23. Qian K., Morris-Natschke S., and Lee K. HIV entry inhibitors and their potential in HIV therapy. Med. Res. Rev. 29 (2009) 369-393
24. Connor R.I., Chen B.K., Choe S., and Landau N.R. Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology 206 (1995) 935-944
25. He J., Choe S., Walker R., Di Marzio P., Morgan D.O., and Landau N.R. Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. J. Virol. 69 (1995) 6705-6711
26. Rong L., and Bates P. Analysis of the subgroup A avian sarcoma and leukosis virus receptor: the 40-residue, cysteine-rich, low-density lipoprotein receptor repeat motif of Tva is sufficient to mediate viral entry. J. Virol. 69 (1995) 4847-4853
27. Guo Y., Yu X., Rihani K., Wang Q.Y., and Rong L. The role of a conserved acidic residue in calcium-dependent protein folding for a low density lipoprotein (LDL)-A module: implications in structure and function for the LDL receptor superfamily. J. Biol. Chem. 279 (2004) 16629-16637
28. Li F., Li W., Farzan M., and Harrison S.C. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science 309 (2005) 1864-1868
29. Deng Y., Liu J., Zheng Q., Yong W., and Lu M. Structures and polymorphic interactions of two heptad-repeat regions of the SARS virus S2 protein. Structure 14 (2006) 889-899